Observational studyCancer causes & control : CCC2025
HPV vaccination in community health organizations: what is going right and how can it be replicated?
Observational study in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHuman papillomavirus (HPV) vaccination is recommended for individuals between 9 and 12 years of age to prevent six different cancers. Lower rates of vaccination exist among underserved populations. We evaluate rates of up-to-date (UTD) HPV vaccination within a nationwide network representing many medically underserved communities.
methodsThis study was conducted using OCHIN, a diverse national database of over 6 million publicly or underinsured patients seen at an OCHIN clinic from January 2015 to December 2023. HPV vaccination initiation and completion rates were the primary outcomes.
results1,848,813 patients were included. HPV vaccination rates for all races and ethnic groups were below the Healthy People 2030 goal of 80.0%. Vaccination varied by race/ethnicity, with Hispanic individuals having the highest rates of UTD vaccination. There was no statistically significant difference between male and female genders for HPV vaccination. Odds of successful completion of the vaccine series were highest when series initiation occurred at ages 9-10 and among those with at least two clinical visits per year.
conclusionsHPV vaccination completion rates remain below the national goal among all ages and racial/ethnic groups in this large, nationwide cohort though all rates increased throughout the study period for most groups. Hispanic race, younger age at initiation, and higher number of clinical visits had increased odds of HPV vaccination. Notably, the gap between males and females closed. Exploration in how these clinics is appealing to the Hispanic population; caregivers of younger children and the male population should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.